The impact of progression‐directed therapy on survival in metastatic castration‐refractory prostate cancer: MEDCARE phase 3 trial

Documenti analoghi

• Percentage of free to total PSA as a biomarker of survival in metastatic castration‐resistant prostate cancer
  di: Andrew W. Silagy, et al.
  Pubblicazione: (2025)
• Authors’ reply to: comment on ‘Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer’
  di: Lies Van den Eynde, et al.
  Pubblicazione: (2025)
• Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer
  di: Lies Van den Eynde, et al.
  Pubblicazione: (2025)
• Characteristics and outcomes of men presenting with complications of metastatic prostate cancer
  di: Arjun Nathan, et al.
  Pubblicazione: (2026)
• Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer
  di: Michiel Vlaming, et al.
  Pubblicazione: (2025)